RESEARCH TRIANGLE PARK, NC--(Marketwire - July 30, 2008) - By 2012, sales of monoclonal
antibodies will represent nearly 50% of oncology drug sales, according to a
new study by Cutting Edge Information.
Successful brands such as Rituxan, Herceptin and Erbitux are all expected
to grow by anywhere from 23% to 80% by 2013. Furthermore, there are
several monoclonal antibodies, such as Amgen's Denosumab and Bristol-Myers
Squibb's ipilumumab, in development poised to experience similar growth
after they launch.
The new report, "The Oncology Market Forecast to 2013," is a comprehensive
study of more than 135 oncology drugs. The study includes detailed
forecasts for each drug, including forecasts for individual drug classes
and top oncology drug manufacturers. Download a complimentary brochure
here:
http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp
"In this era where blockbuster drugs are few and far between, the cancer
market is one area that is poised for tremendous growth," said Eric Bolesh,
research team leader at Cutting Edge Information. "The amount of research
dollars that the pharma industry is spending on oncology drug development
is sure to deliver new market leaders in the next five years."
Monoclonal antibodies' (MAbs) efficacy and diminished side effects make
them an attractive choice for oncologists. In 2007, MAb sales leapt by $3
billion over 2006 levels to almost $14 billion. This increase comes thanks
to the three highest-selling MAbs -- Herceptin, Rituxan and Avastin, which
combined for more than $12.4 billion in 2007 after 2006 sales of $9.7
billion.
MAb sales will continue to grow by a steady $2 billion to $3 billion per
year. Herceptin, Rituxan, Avastin and Erbitux will maintain market
dominance with nearly $25 billion in sales by 2012, or 89% of the MAb
market. In addition, six new MAbs are slotted for launch in the next two
years.
The 420+ page study examines 17 monoclonal antibodies and more than 120
other drugs, and provides the following market analysis:
-- Individual Drug Profiles - Drug profiles include information about
drugs' competitive, strategic and market growth positions.
-- Oncology Indication Market Outlook - Detailed outlooks for the breast,
colorectal, lung and prostate cancer and leukemia markets.
-- Company Profiles - Oncology breakdowns for companies that either have
established oncology franchises or exciting development pipelines for new
cancer compounds.
Contact Information: CONTACT INFORMATION:
Eric Bolesh
919-433-0209